{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:54:21Z","timestamp":1773017661217,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.1006\/gyno.2001.6365","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T22:50:18Z","timestamp":1032303018000},"page":"257-262","source":"Crossref","is-referenced-by-count":51,"title":["Improved Therapeutic Index of Lower Dose Topotecan Chemotherapy in Recurrent Ovarian Cancer"],"prefix":"10.1006","volume":"83","author":[{"given":"Michael","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2001.6365_RF1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","article-title":"Cancer statistics, 2001","volume":"51","author":"Greenlee","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"10.1006\/gyno.2001.6365_RF2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2001.6365_RF3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Randomized trial of standard dose intravenous cisplatin\/paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF4","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plant tumor agents I. The isolation and structure of campotothecin a novel alkaloid leukemia and tumor inhibitor from camptotheca acuminata","volume":"88","author":"Wall","year":"1966","journal-title":"J Am Chem Soc"},{"key":"10.1006\/gyno.2001.6365_RF5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/jm00105a017","article-title":"Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase 1 and antitumor activity","volume":"34","author":"Kingsbury","year":"1991","journal-title":"J Med Chem"},{"key":"10.1006\/gyno.2001.6365_RF6","first-page":"515","article-title":"Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies","volume":"56","author":"Muggia","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1006\/gyno.2001.6365_RF7","first-page":"573","article-title":"Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment relation to dose and toxicity","volume":"56","author":"Creaven","year":"1972","journal-title":"Cancer Chemother Rep"},{"key":"10.1006\/gyno.2001.6365_RF8","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF9","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.1999.5640","article-title":"Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial","volume":"75","author":"Markman","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2001.6365_RF11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/gyno.2000.5755","article-title":"Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study","volume":"77","author":"Markman M; Blessing","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2001.6365_RF12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/gyno.2000.5844","article-title":"A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2001.6365_RF13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.3-1-4","article-title":"Clinical guidelines for managing topotecan-related hematologic toxicity","volume":"3","author":"Armstrong","year":"1998","journal-title":"Oncologist"},{"key":"10.1006\/gyno.2001.6365_RF14","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.1996.14.12.3062","article-title":"Phase I and pharmacologic study of topotecan in patients with impaired renal function","volume":"14","author":"O'Reilly","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF16","first-page":"S19","article-title":"Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma","volume":"24","author":"ten Bokkel Huinink","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF18","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF19","first-page":"6039","article-title":"Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells","volume":"51","author":"Chen","year":"1991","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2001.6365_RF20","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/oxfordjournals.annonc.a058623","article-title":"Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor","volume":"4","author":"Verweij","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1006\/gyno.2001.6365_RF22","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/jnci\/85.18.1499","article-title":"Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors with attempt at dose intensification using recombinant granulocyte colony-stimulating factor","volume":"85","author":"Saltz","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2001.6365_RF23","first-page":"769a","article-title":"A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer","volume":"14","author":"Armstrong","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF24","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2001.6365_RF26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.2000.18.5.1062","article-title":"Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"18","author":"McGuire","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF27","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/84.23.1816","article-title":"Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro","volume":"84","author":"Burris HA 3rd","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2001.6365_RF28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","article-title":"Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors","volume":"31","author":"Houghton","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1006\/gyno.2001.6365_RF29","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"13","author":"McGuire","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF30","first-page":"284","article-title":"A randomized study of high versus standard dose carboplatin in patients with advanced epithelial ovarian cancer","volume":"15","author":"Gore","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF31","first-page":"279","article-title":"Prospective randomized trial of cisplatin and carboplatin versus conventional cisplatin\/cyclophosphamide in epithelial ovarian cancer first results of the impact of platinum dose intensity of patient outcome","volume":"15","author":"Dittrich","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF32","first-page":"284","article-title":"Meta analysis of paclitaxel dose response and dose intensity in recurrent or refractory ovarian cancer","volume":"15","author":"Rowinsky","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF33","first-page":"280","article-title":"A randomized trial of paclitaxel at 2 dose levels and filgastrim at 2 dose levels in platinum pretreated epithelial ovarian cancer","volume":"15","author":"Omura","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF34","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European\u2013Canadian randomized trial of paclitaxel in relapsed ovarian cancer high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6365_RF35","first-page":"1233","article-title":"Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients","volume":"15","author":"Cesano","year":"1999","journal-title":"Int J Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825801963656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825801963656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T04:21:46Z","timestamp":1620015706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825801963656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["S0090825801963656"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2001.6365","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}